Leadership Overview
Eris Lifesciences has 4 executives leading key functions including operational strategy, marketing, corporate governance, and manufacturing oversight.
Focused on advancing patient care within the cardio-metabolic sector, Eris Lifesciences delivers innovative branded formulations to address chronic lifestyle-related diseases across the Indian pharmaceutical market.
Focused on advancing patient care within the cardio-metabolic sector, Eris Lifesciences delivers innovative branded formulations to address chronic lifestyle-related diseases across the Indian pharmaceutical market.
Leadership Roles at Eris Lifesciences
V. Krishnakumar - Executive Director & Chief Operating Officer
V. Krishnakumar, the Executive Director & Chief Operating Officer at Eris Lifesciences, manages the daily operational infrastructure required to maintain high-quality pharmaceutical production. This leadership role involves coordinating cross-functional teams to ensure that branded formulations reach healthcare professionals efficiently across the Indian market. By optimizing supply chain logistics and manufacturing workflows, the Executive Director & Chief Operating Officer drives significant improvements in operational throughput. V. Krishnakumar also collaborates with the Board to align internal processes with long-term growth objectives in the cardio-metabolic sector. Through rigorous oversight of resource allocation and process engineering, the Executive Director & Chief Operating Officer maintains the company's competitive edge in dermatology and gynecology. This position demands constant vigilance over production standards and regulatory compliance. Ultimately, Krishnakumar secures the operational stability necessary for the company to deliver consistent health outcomes for patients nationwide.
R. Murari - President
R. Murari, the President at Eris Lifesciences, directs the overarching corporate strategy and long-term vision for the organization. This leadership role involves guiding the company through complex market shifts within the Indian pharmaceutical landscape. By overseeing the integration of new therapeutic areas like dermatology and gynecology, the President ensures that the business model remains agile and responsive to patient needs. R. Murari also facilitates high-level discussions with the Board to prioritize capital investments in research and development. Through the management of executive leadership teams, the President maintains a focus on sustainable growth and operational excellence. This position requires balancing immediate financial performance with the pursuit of pioneering studies in chronic disease management. By fostering a culture of innovation, the President drives the company toward its goal of improving health outcomes. Ultimately, Murari secures the strategic direction required for continued success in the competitive cardio-metabolic sector.
Gagan Atreja - President, Operations
Gagan Atreja, the President, Operations at Eris Lifesciences, oversees the technical execution and manufacturing capabilities that support the company's diverse product range. This leadership role involves managing the production facilities to ensure that all anti-diabetes and cardiovascular medications meet stringent quality standards. By directing regional manufacturing initiatives, the President, Operations optimizes the efficiency of the entire supply chain. Gagan Atreja also coordinates with the research teams to scale new formulations from development to commercial production. Through the implementation of advanced manufacturing technologies, the President, Operations drives cost-effectiveness and product reliability. This function requires constant interaction with quality control departments to maintain regulatory compliance across all facilities. By streamlining internal processes, the President, Operations supports the company's mission to provide accessible healthcare solutions. Ultimately, Atreja ensures that the operational backbone of the organization remains robust enough to meet the growing demands of the Indian pharmaceutical market.
Manoj Mallick - Markrting
Manoj Mallick, the Markrting at Eris Lifesciences, architects the promotional strategies that connect branded formulations with healthcare professionals throughout India. This leadership role involves analyzing market trends in the anti-diabetes and cardiovascular health segments to refine product positioning. By directing national campaigns, the Markrting ensures that medical practitioners receive accurate information regarding therapeutic benefits. Manoj Mallick also manages the engagement programs that support patient education initiatives for chronic lifestyle-related diseases. Through data-driven insights, the Markrting identifies emerging opportunities for market expansion and brand differentiation. This function requires close coordination with sales teams to maximize the impact of product launches. By fostering strong relationships with the medical community, the Markrting drives revenue growth and enhances the company's reputation for excellence. Ultimately, Mallick strengthens the market presence of the entire product portfolio through strategic communication and targeted outreach efforts.
Explore Leadership Teams in Manufacturing
GSK plc is a British multinational pharmaceutical and biotechnology company headquartered in London, United Kingdom. Established in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, GSK is the tenth-largest pharmaceutical company globally. The company discovers, develops, manufactures, and delivers medicines and vaccines with a research and development focus on four primary therapeutic areas: respiratory, immunology and inflammation, oncology, HIV, and infectious diseases. GSK's product portfolio includes specialty medicines, vaccines, and general medicines targeting conditions such as HIV, respiratory diseases, cancer, immuno-inflammation, anti-viral, central nervous system disorders, metabolic conditions, cardiovascular disease, urogenital conditions, anti-bacterial treatments, dermatology, and rare diseases. The company also offers over-the-counter products for pain relief, oral health, nutrition, skin health, and gastrointestinal diseases. GSK has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. In July 2024, the company moved its global headquarters to New Oxford Street in central London, positioning itself within the city's Knowledge Quarter near world-class science and academic institutions including the Francis Crick Institute and King's College London. The new headquarters houses approximately 3,000 employees including the global leadership team and teams supporting research and development, supply chain, commercial operations, and corporate functions. GSK sells its products through wholesalers, pharmacies, hospitals, physicians, and other healthcare groups globally, aiming to positively impact the health of 2.5 billion people by the end of the decade.
Company Leadership LT
PL
RH
Sarepta Therapeutics, Inc. is a global commercial-stage biopharmaceutical company founded in 1980 and headquartered in Cambridge, Massachusetts. The company is focused on the discovery, development, and commercialization of precision genetic medicines for rare diseases, with particular leadership in Duchenne muscular dystrophy and limb-girdle muscular dystrophies. Sarepta's multi-platform Precision Genetic Medicine Engine spans gene therapy, RNA-targeted therapeutics, and gene editing modalities. The company holds multiple FDA-approved treatments and maintains a broad pipeline of programs across neuromuscular and central nervous system disorders. Sarepta operates globally with locations across North America, Europe, and Asia, and trades on the NASDAQ under the ticker symbol SRPT.
Company Leadership
AN
KM
Santa Farma is a prominent pharmaceutical company in Turkey, leading the healthcare sector since 1944 with a wide range of medications produced using modern manufacturing techniques. The company has built a strong reputation and trust in the industry through licensed production and multinational collaborations. Santa Farma is committed to values such as sensitivity to people, openness to development, rational strength, and respect for work, workplace, and society. Their products and services are primarily aimed at healthcare professionals.
Company Leadership SK
JD
EA
DA
Since 2006, Pharos Indonesia has been the fastest growing pharmaceutical company in Indonesia, achieving 40% annual growth. In 2009, based on IMS* reports, Pharos became the 4th largest Indonesian pharmaceutical company; jumping from position 12 in just 4 years. Pharos marketing teams have forged strong relationships with major hospital groups as well as individual doctors, including specialists and this ensures strong distribution of our products. No other pharmaceutical manufacturer, nor retail pharmacy group, can compete with the strength of the Pharos-controlled network of almost 2,000 pharmacies spread across Indonesia. Pharos is uniquely positioned to take advantage of the large and fast-growing ASEAN region.
Company Leadership VP
RR
AL
HD
Frequently Asked Questions Regarding Eris Lifesciences Top Executives and Leadership Team
